This inventor holds 1 USPTO granted patent. Top assignee: Hsc Research and Development Limited Partnership. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Wei Wang - Innovator in Mammalian Protein Research
Introduction
Wei Wang is a prominent inventor based in Toronto, Canada. He has made significant contributions to the field of molecular biology, particularly in the study of mammalian proteins. His work focuses on the identification and characterization of proteins that play crucial roles in cellular processes.
Latest Patents
Wei Wang holds a patent for his invention related to the Ese genes and proteins. The patent describes the identification, isolation, and characterization of novel mammalian proteins encoded by the Ese1 and Ese2 genes. These proteins are involved in endocytosis, vesicular trafficking, and the regulation of the actin cytoskeleton. The transcripts and products of these genes are valuable for detecting abnormal cellular endocytosis processes. They also have potential applications in developing assay systems to identify further binding partners of the proteins, creating therapeutics to alter or restore protein function, and isolating and manufacturing Ese proteins. He has 1 patent to his name.
Career Highlights
Wei Wang is associated with HSC Research and Development Limited Partnership, where he continues to advance his research. His work has implications for understanding cellular mechanisms and developing therapeutic strategies.
Collaborations
Wei collaborates with notable colleagues, including Ameet Sengar and Sean E Egan, who contribute to his research endeavors.
Conclusion
Wei Wang is a dedicated inventor whose work in mammalian protein research has the potential to impact various scientific and medical fields. His innovative contributions continue to pave the way for advancements in understanding cellular processes and developing new therapeutic approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile